Unknown

Dataset Information

Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause.


ABSTRACT:

Objective

Sleep disturbances are common among women in midlife; prevalence increases among perimenopausal/postmenopausal women with vasomotor symptoms. Paroxetine 7.5 mg is the only nonhormonal treatment that has been approved in the United States for moderate to severe vasomotor symptoms associated with menopause. In two pivotal phase 3 studies evaluating its efficacy and safety, improvements in sleep disturbances were also prospectively evaluated.

Methods

Postmenopausal women with moderate to severe vasomotor symptoms were randomly assigned to paroxetine 7.5 mg (n = 591) or placebo (n = 593) once daily for 12 weeks (both studies) or 24 weeks (24-wk study). Predefined assessments on weeks 4, 12, and 24 included number of nighttime awakenings attributed to vasomotor symptoms

SUBMITTER: Pinkerton JV 

PROVIDER: S-EPMC4274337 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature